Clinical review report: Riociguat (Adempas)
The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III)
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 2015, 2015
|
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references